论文部分内容阅读
Anistreplase(APSAC):茴香酰化纤溶酶原链激酶激活剂复合剂,是最近发现并应用于治疗急性心肌梗塞(AMI)的新药,只需一次静脉冲击量给药的溶栓剂。〈临床研究〉许多临床研究均证明了APSAC作为一种溶栓剂治疗AMI的效果。Bonnier等人发现,与冠脉内用链激酶相比,5分钟内给予30uAPSAC使冠脉再通(68%比64%),而后者的冠脉再通时间短(45分钟),再闭塞率低(5%)。APSAC还可以缩小心肌梗塞范围和保护左室功能。Bassand等人将5分钟内给予30uAPSAC与肝素治疗AMI相比较,发现有77%的再通,经单光子发射型计算机断层术测定、可缩小梗塞范围13%,并可保护左室收缩功能(LVEF53%比47%)。在其另
Anistreplase (APSAC): An anisoylated plasminogen streptokinase activator complex, is a recently discovered and used in the treatment of acute myocardial infarction (AMI) of new drugs, only a single intravenous dose administration of thrombolytic agents. Many clinical studies have demonstrated the efficacy of APSAC as a thrombolytic agent in the treatment of AMI. Bonnier et al. Found that administration of 30 uAPSAC within 5 minutes led to recanalization of the coronary artery (68% vs. 64%) compared with coronary streptokinase, while the latter had a short reperfusion time (45 minutes) and a reocclusion rate Low (5%). APSAC can also reduce myocardial infarct size and protect left ventricular function. Bassand and colleagues compared 77% recanalization with heparin-treated AMI in 5 minutes given 30uAPSAC, which reduced infarct size by 13% by single photon emission computed tomography and preserved left ventricular systolic function (LVEF53 % To 47%). In its other